Amgen NASDAQ: AMGN p. farmaceutyczny, biotechnologiczny
Amgen NASDAQ: AMGN p. farmaceutyczny, biotechnologiczny
wykres
http://finance.yahoo.com/echarts?s=amgn+Interactive
https://stockcharts.com/h-sc/ui?s=AMGN
Amgen NASDAQ: AMGN - amerykańskie przedsiębiorstwo biofarmaceutyczne z siedzibą
w Thousand Oaks w Kalifornii, założone w 1980 roku.
W 2015 roku przedsiębiorstwo posiadało patenty na 10 leków:
Neulasta (pegfilgrastym) - lek stosowany w neutropenii.
Enbrel (etanercept) - stosowany przy zapaleniu stawów.
Prolia/XGEVA (denosumab) - stosowany przy osteoporozie.
EPOGEN (epoetyna alfa) - stosowany przy chorobach nerek.
Aranesp (darbopoetyna alfa) - stosowany przy chorobach nerek.
Sensipar/Mimpara (cynakalcet) - stosowany przy chorobach przytarczyc.
Vectibix (penitumumab) - stosowany przy raku jelita grubego.
Nplate (romiplostym) - stosowany w leczeniu plamicy małopłytkowej.
Kyprolis (carfilzomib - lek stosowany w leczeniu szpiczaka mnogiego).
BLINCYTO (blinatumomab) - lek stosowany w leczeniu białaczki limfoblastycznej.
http://www.amgen.pl/
http://en.wikipedia.org/wiki/Amgen
http://www.amgen.com/
wątek o spółce
http://www.thelion.com/bin/aio_msg.cgi? ... gn&x=0&y=0
http://www.hotstockmarket.com/t/35478/amgn-amgen-inc/80
dywidendy
https://finviz.com/quote.ashx?t=AMGN
https://seekingalpha.com/symbol/AMGN/di ... /scorecard
http://investors.amgen.com/phoenix.zhtm ... -dividends
https://www.streetinsider.com/dividend_ ... php?q=amgn
Ostatnio zmieniony 07 lut 2022 19:37 przez slayer74, łącznie zmieniany 9 razy.
Pieniądz robi pieniądz a bieda robi jeszcze wiekszą biedę !!!
REKLAMA
http://finance.yahoo.com/news/amgen-top ... 06270.html
ATechniczna - rekord wszech czasów przy dużym wzroście obrotów
Na parkiecie o 6,1 proc. podskoczył kurs spółki Amgen, która podwyższyła swoją roczną prognozę. pb.pl
ATechniczna - rekord wszech czasów przy dużym wzroście obrotów
Na parkiecie o 6,1 proc. podskoczył kurs spółki Amgen, która podwyższyła swoją roczną prognozę. pb.pl
Pieniądz robi pieniądz a bieda robi jeszcze wiekszą biedę !!!
Re: Amgen NASDAQ: AMGN
ATechniczna - testowanie rekordów wszech czasów
Pieniądz robi pieniądz a bieda robi jeszcze wiekszą biedę !!!
Re: Amgen NASDAQ: AMGN
Amgen Announces 15 Percent Increase In 2017 First Quarter Dividend
http://wwwext.amgen.com/media/news-rele ... -dividend/
http://wwwext.amgen.com/media/news-rele ... -dividend/
Pieniądz robi pieniądz a bieda robi jeszcze wiekszą biedę !!!
Re: Amgen NASDAQ: AMGN p. farmaceutyczny
Amgen Topples After Fourth-Quarter Sales, Earnings Lag
https://www.investors.com/news/technolo ... nings-lag/
https://www.investors.com/news/technolo ... nings-lag/
Pieniądz robi pieniądz a bieda robi jeszcze wiekszą biedę !!!
Re: Amgen NASDAQ: AMGN p. farmaceutyczny
Amgen Wins Another FDA Approval
https://247wallst.com/healthcare-busine ... -approval/
https://247wallst.com/healthcare-busine ... -approval/
Pieniądz robi pieniądz a bieda robi jeszcze wiekszą biedę !!!
Re: Amgen NASDAQ: AMGN p. farmaceutyczny
Amgen Crushes Second-Quarter Revenue, Profit Expectations
https://www.investors.com/news/technolo ... -earnings/
https://www.investors.com/news/technolo ... -earnings/
Pieniądz robi pieniądz a bieda robi jeszcze wiekszą biedę !!!
Re: Amgen NASDAQ: AMGN p. farmaceutyczny
Biotech giant Amgen (AMGN) could be nearing a deal to buy Alexion Pharmaceuticals (ALXN) at a 74% premium, according to a Spanish news outlet.
https://www.investors.com/news/technolo ... on-pharma/
https://www.investors.com/news/technolo ... on-pharma/
Pieniądz robi pieniądz a bieda robi jeszcze wiekszą biedę !!!
Re: Amgen NASDAQ: AMGN p. farmaceutyczny
Why Amgen Is Called to Outperform Large-Cap Biotechs?
In 2020 investors have been forced to dial down expectations in biotech if their business ambitions are not tied to COVID-19. The reality is that all of the world’s other health problems have not gone away. These still need ongoing treatments and cures, and valuations in the top large-cap biotechs are just not expensive and they should have plenty of earnings resilience compared to non-health sectors in the recession. Amgen Inc. (NASDAQ: AMGN) made history by recently becoming the first biotech company to ever join the Dow Jones Industrial Average. Credit Suisse sees more than 20% upside ahead.
Credit Suisse’s Evan Seigerman and the research team have an Outperform rating and $290 price target that implies more than 20% upside, and Amgen has a 2.6% dividend yield to boot.
The brokerage firm noted that the overall response rate (ORR) in the 960 mg cohort for non small cell lung cancer fell to 35.3%, but the overall median duration of response (mDOR) of 10.9 months was strong.
Credit Suisse said this in its report:
We would characterize these data as better than expected and generally positive given the ORR in the mid-30% range for the 960 mg cohort. We also note that the mDOR of 10.9 months is well above the six-month benchmark and is across all dose-levels and that the data are not yet mature enough for a mDOR calculation in the 960 mg cohort.
We still believe that a 30% ORR with at least 6 months duration of response remains the low-end of the bar for potential approval as monotherapy. In our view this data is not a “grand-slam,” but we would consider this to be highly encouraging for the ongoing KRAS G21C development programs of both AMG 510 and MRTX 849.
Separately, Amgen’s Dr. David Reese, EVP of R&D, and Dr. Gregory Friberg, VP of Global Development and Oncology provided some additional color on the firm’s broader Bispecific T-cell Engager (BiTE) platform.
Overall, the aim of the BiTE platform is to represent an ‘off the shelf’ T-cell-based therapy and to move into earlier lines of therapy as the program develops (potentially in combination with checkpoint inhibitors).
Management believes the efficacy demonstrated in metastatic castration-resistant prostate cancer (mCRPC) is encouraging for other solid tumors even though each target’s safety profile is likely to be different. The development cycle is still in its early stages.
Amgen stock was last seen at $238.49, with a 52-week range of $177.05 to $264.97. The consensus analyst price target is $262.76.
https://247wallst.com/healthcare-busine ... -biotechs/
In 2020 investors have been forced to dial down expectations in biotech if their business ambitions are not tied to COVID-19. The reality is that all of the world’s other health problems have not gone away. These still need ongoing treatments and cures, and valuations in the top large-cap biotechs are just not expensive and they should have plenty of earnings resilience compared to non-health sectors in the recession. Amgen Inc. (NASDAQ: AMGN) made history by recently becoming the first biotech company to ever join the Dow Jones Industrial Average. Credit Suisse sees more than 20% upside ahead.
Credit Suisse’s Evan Seigerman and the research team have an Outperform rating and $290 price target that implies more than 20% upside, and Amgen has a 2.6% dividend yield to boot.
The brokerage firm noted that the overall response rate (ORR) in the 960 mg cohort for non small cell lung cancer fell to 35.3%, but the overall median duration of response (mDOR) of 10.9 months was strong.
Credit Suisse said this in its report:
We would characterize these data as better than expected and generally positive given the ORR in the mid-30% range for the 960 mg cohort. We also note that the mDOR of 10.9 months is well above the six-month benchmark and is across all dose-levels and that the data are not yet mature enough for a mDOR calculation in the 960 mg cohort.
We still believe that a 30% ORR with at least 6 months duration of response remains the low-end of the bar for potential approval as monotherapy. In our view this data is not a “grand-slam,” but we would consider this to be highly encouraging for the ongoing KRAS G21C development programs of both AMG 510 and MRTX 849.
Separately, Amgen’s Dr. David Reese, EVP of R&D, and Dr. Gregory Friberg, VP of Global Development and Oncology provided some additional color on the firm’s broader Bispecific T-cell Engager (BiTE) platform.
Overall, the aim of the BiTE platform is to represent an ‘off the shelf’ T-cell-based therapy and to move into earlier lines of therapy as the program develops (potentially in combination with checkpoint inhibitors).
Management believes the efficacy demonstrated in metastatic castration-resistant prostate cancer (mCRPC) is encouraging for other solid tumors even though each target’s safety profile is likely to be different. The development cycle is still in its early stages.
Amgen stock was last seen at $238.49, with a 52-week range of $177.05 to $264.97. The consensus analyst price target is $262.76.
https://247wallst.com/healthcare-busine ... -biotechs/
Pieniądz robi pieniądz a bieda robi jeszcze wiekszą biedę !!!
Re: Amgen NASDAQ: AMGN p. farmaceutyczny
Undervalued Dividend Growth Stock of the Week: Amgen (AMGN)
https://dailytradealert.com/2020/12/20/ ... mgen-amgn/
https://www.youtube.com/watch?v=yYJAdNg ... sAndIncome
https://dailytradealert.com/2020/12/20/ ... mgen-amgn/
https://www.youtube.com/watch?v=yYJAdNg ... sAndIncome
Pieniądz robi pieniądz a bieda robi jeszcze wiekszą biedę !!!
Re: Amgen NASDAQ: AMGN p. farmaceutyczny
Amgen (NASDAQ:AMGN) stock fell 2.5% after the biotech company disappointed with its 2021 earnings guidance even after reporting better-than-expected quarterly profit.
Pieniądz robi pieniądz a bieda robi jeszcze wiekszą biedę !!!
REKLAMA
Kto jest online
Użytkownicy przeglądający to forum: Obecnie na forum nie ma żadnego zarejestrowanego użytkownika i 19 gości